Recombinant Cytomegalovirus Cytomegalovirus gH Pentamer Complex VR1814 His (C-Term) Protein
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-14809
Discontinued Product
NBP3-14809 has been discontinued.
View all Cytomegalovirus gH Pentamer Complex products.
Key Product Details
Source
HEK293
Tag
His (C-Term)
Conjugate
Unconjugated
Applications
SDS-PAGE
Product Specifications
Description
Recombinant human cytomegalovirus pentamer protein complex (NCBI Accession#: ACZ79986), consisting of proteins UL75 (gH), UL115 (gL), UL128, UL130 and UL131A, contains a His-tag.
Concentration: 1.0-1.5mg/ml
Concentration: 1.0-1.5mg/ml
Purity
>95% pure by SDS-PAGE
Application Notes
Purified protein binds NRP-2 receptor in ELISA.
Specificity
Cytomegalovirus gH Pentamer Complex comprises five viral proteins (gH, gL, UL128, UL130, and UL131A). This complex has been shown to bind our recombinant NRP-2 protein in ELISA.
Protein / Peptide Type
Recombinant Protein
Scientific Data Images
SDS-PAGE: Recombinant Cytomegalovirus Cytomegalovirus gH Pentamer Complex VR1814 His (C-Term) Protein [NBP3-14809]
SDS-Page: Cytomegalovirus gH Pentamer Complex Recombinant Protein Antigen [NBP3-14809] - Coomassie-stained SDS-PAGE showing Cytomegalovirus gH Pentamer Complex.Formulation, Preparation and Storage
NBP3-14809
| Formulation | Dulbecco's PBS, 0.2 um filter sterilised. |
| Preservative | No Preservative |
| Concentration | Please see the vial label for concentration. If unlisted please contact technical services. |
| Shipping | The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Store at -80C. Avoid freeze-thaw cycles. |
Background: Cytomegalovirus gH Pentamer Complex
Cytomegalovirus is a common virus, infecting ~60% of adults in developed countries and over 90% in developing countries, as indicated by presence of specific IgG antibodies (2-4). Although a majority of people infected remain asymptomatic, immunocompromised people, organ transplant recipients, and fetuses and newborns are more susceptible to HCMV-associated diseases (1-4). Annually, up to 2% of newborns are born with HCMV, making it the most common congenital infection (2-4). Cytomegalovirus is known to cause sensorineural hearing loss (SNHL), mental retardation, chorioretinitis, skin lesions, as well as end organ disease (3,5). There are a few CMV therapeutics approved by FDA including valganciclovir and letermovir; however, despite some benefits, there is the need for new antivirals and combination therapies (5). Potential new treatment options include monoclonal antibodies and sirtuins (5).
References
1. Connolly SA, Jardetzky TS, Longnecker R. The structural basis of herpesvirus entry. Nat Rev Microbiol. 2021;19(2):110-121. https://doi.org/10.1038/s41579-020-00448-w
2. Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021;19(12):759-773. https://doi.org/10.1038/s41579-021-00582-z
3. Krstanovic F, Britt WJ, Jonjic S, Brizic I. Cytomegalovirus Infection and Inflammation in Developing Brain. Viruses. 2021;13(6):1078. Published 2021 Jun 4. https://doi.org/10.3390/v13061078
4. Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus. J Pathol. 2015;235(2):288-297. https://doi.org/10.1002/path.4437
5. Acosta E, Bowlin T, Brooks J, et al. Advances in the Development of Therapeutics for Cytomegalovirus Infections. J Infect Dis. 2020;221(Suppl 1):S32-S44. https://doi.org/10.1093/infdis/jiz493
Alternate Names
envelope glycoprotein H
Product Specific Notices
This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...